AOD-9604

AOD-9604 is a synthetic fragment of human growth hormone, specifically designed to retain GH's fat-metabolism effects without the insulin resistance, fluid retention, or IGF-1 elevation that full GH carries. Community use centers on fat loss and weight management, with clinician protocols typically running 300–500 mcg/day via subcutaneous injection, timed to bedtime or a fasted morning window, for cycles of 8–24 weeks. The honest caveat: every human use is off-label — AOD-9604 has no approved indication anywhere — so you're operating entirely on compounded supply and a limited evidence base.

AOD-9604

Research Evidence

Evidence shape

No registered clinical trials exist for AOD-9604, and no human indications have been mapped from any clinical data. This is not a sparse or early-stage file — it is a complete absence of clinical record. There is no trial to cite, no posted result to evaluate, and no indication that has reached controlled human testing; the zero here is the finding, not a placeholder for work in progress.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 thin / exploratory
Qualityhow rigorous
No completed trials
Breadth and depth1 row captured
Human
direct clinical signal
0
Animal
translational support
0
In vitro
mechanistic support
1
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
UK
2400 mg
$45.75
$0.013/mg
2
US
5 mg
$0.52
$0.104/mg
3
US
5 mg
$1.00
$0.2/mg
4
UK
50 mg
$35.03
$0.701/mg
5
HK
50 mg
$90.00
$1.8/mg
6
--
50 mg
$115.33
$2.31/mg

price offers can be sorted by column

1-6 of 113

Dosing & Protocol

How AOD-9604 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance · n = 4
Typical dose
300 µg250 µg – 500 µg
250 µg
500 µg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 250 µg–500 µg daily subQ (4 sources).

4 sources
Anecdotal
Community-reported real-world use · n = 22
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports show varied efficacy. Of 20 reports on targeted fat loss, 80% were positive. For cartilage repair, 50% of 2 reports were positive. Specific dosing figures were not consistently reported in community posts.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for AOD-9604, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.